TY - JOUR
T1 - Greek translation of a summary of the 2017 update of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology
AU - Schoretsanitis, G.
AU - Pallis, E. G.
AU - Paulzen, M.
AU - Unterecker, S.
AU - Schwarz, M.
AU - Conca, A.
AU - Zernig, G.
AU - Gründer, G.
AU - Haen, E.
AU - Baumann, P.
AU - Bergemann, N.
AU - Domschke, K.
AU - Eckermann, G.
AU - Egberts, K.
AU - Gerlach, M.
AU - Greiner, C.
AU - Hefner, G.
AU - Jaquenoud, E.
AU - Laux, G.
AU - Messer, T.
AU - Müller, M. J.
AU - Riederer, P.
AU - Saria, A.
AU - Stegmann, B.
AU - Steimer, W.
AU - Stingl, J.
AU - Uhr, M.
AU - Ulrich, S.
AU - Waschgler, R.
AU - Zurek, G.
AU - Hiemke, C.
N1 - Publisher Copyright:
© 2021, BETA Medical Publishers Ltd. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - The quantification and pharmacological interpretation of drug concentrations in blood (serum or plasma) is widely known as therapeutic drug monitoring (TDM). In clinical practice, TDM is an established precision tool that pro-vides the fundamental prerequisites for personalized treatment. Specifically, in neurology and psychiatry, TDM can be used as part of the process of prescription of medications in specific patient subgroups, including children and adolescents, pregnant women, elderly patients, patients with intellectual disabilities, patients with substance abuse disorders, individuals with pharmacokinetic idiosyncrasies and forensic patients. Clinicians may consider TDM in the case of lack of clinical response to therapeutic doses of medication, assessment of drug adherence, tolerability and drug-drug interactions. This is the Greek translation of a short summary of the updated consensus guidelines com-piled by the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). It includes therapeutic reference ranges, laboratory alert levels, recommendation levels for prescribing TDM for dosage optimization without specific indications, conversion factors, factors for calculation of dosage-related drug concentrations and metabolite-to-parent ratios.
AB - The quantification and pharmacological interpretation of drug concentrations in blood (serum or plasma) is widely known as therapeutic drug monitoring (TDM). In clinical practice, TDM is an established precision tool that pro-vides the fundamental prerequisites for personalized treatment. Specifically, in neurology and psychiatry, TDM can be used as part of the process of prescription of medications in specific patient subgroups, including children and adolescents, pregnant women, elderly patients, patients with intellectual disabilities, patients with substance abuse disorders, individuals with pharmacokinetic idiosyncrasies and forensic patients. Clinicians may consider TDM in the case of lack of clinical response to therapeutic doses of medication, assessment of drug adherence, tolerability and drug-drug interactions. This is the Greek translation of a short summary of the updated consensus guidelines com-piled by the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). It includes therapeutic reference ranges, laboratory alert levels, recommendation levels for prescribing TDM for dosage optimization without specific indications, conversion factors, factors for calculation of dosage-related drug concentrations and metabolite-to-parent ratios.
KW - Antidepressants
KW - Antipsychotics
KW - Mood stabilizers
KW - Psychiatry
KW - Therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=85121254427&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85121254427
SN - 1105-3992
VL - 38
SP - 817
EP - 832
JO - Archives of Hellenic Medicine
JF - Archives of Hellenic Medicine
IS - 6
ER -